Using AI to predict survival in glioma patients based on histopathology images
Histopathology Images Based Survival Prediction of Patients With Primary Glioma Using Deep Learning or Machine Learning
The First Affiliated Hospital of Zhengzhou University · NCT04215224
This study is trying to see if using artificial intelligence to analyze tissue images can help doctors predict how long glioma patients might live.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3500 (estimated) |
| Ages | 1 Year to 90 Years |
| Sex | All |
| Sponsor | The First Affiliated Hospital of Zhengzhou University (other) |
| Locations | 1 site (Zhengzhou, Henan) |
| Trial ID | NCT04215224 on ClinicalTrials.gov |
What this trial studies
This observational registry collects clinical, molecular, and histopathology imaging data from glioma patients to develop artificial intelligence algorithms for survival prediction. By analyzing histopathology images and correlating them with detailed survival and molecular pathology data, the study aims to enhance the accuracy of prognosis for glioma patients. The registry will include over 1000 samples, allowing for a robust dataset to refine predictive models and facilitate personalized treatment approaches.
Who should consider this trial
Good fit: Ideal candidates include patients with a confirmed diagnosis of primary glioma who are undergoing tumor resection and have a life expectancy of more than three months.
Not a fit: Patients without gliomas, insufficient tumor tissue for molecular analysis, or those with severe systemic malfunctions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide more accurate survival predictions for glioma patients, leading to better-informed treatment decisions.
How similar studies have performed: Other studies utilizing artificial intelligence for survival prediction in cancer have shown promising results, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must have radiologically and histologically confirmed diagnosis of primary glioma * Life expectancy of greater than 3 months * Must receive tumor resection * Signed informed consent Exclusion Criteria: * No gliomas * No sufficient amount of tumor tissues for detection of molecular pathology * Patients who are pregnant or breast feeding * Patients who are suffered from severe systematic malfuctions
Where this trial is running
Zhengzhou, Henan
- Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan, China (RECRUITING)
Study contacts
- Study coordinator: Zhenyu Zhang, Dr.
- Email: fcczhangzy1@zzu.edu.cn
- Phone: +86 17839973727
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Glioma, Prognosis, Histopathology imaging, Deep Learning, Machine Learning